• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Adicet Bio, Inc. - Common Stock (NQ:ACET)

    5.095 +0.205 (+4.19%)
    Delayed Quote Updated: 12:49 PM EDT, Oct 15, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Adicet Bio, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 Next >
    News headline image
    Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
    From Adicet Bio, Inc.
    Via Business Wire
    News headline image
    Adicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis
    From Adicet Bio, Inc.
    Via Business Wire
    News headline image
    Adicet Bio to Host Webcast to Present Prula-cel (formerly ADI-001) Clinical Data in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis
    From Adicet Bio, Inc.
    Via Business Wire
    News headline image
    Adicet Bio to Participate in Fireside Chat at H.C. Wainwright 28th Annual Global Investment Conference
    From Adicet Bio, Inc.
    Via Business Wire
    News headline image
    Adicet Bio Announces Completion of Last Patient Visit for Planned Analysis of prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus With or Without Lupus Nephritis and Provides Corporate Update
    From Adicet Bio, Inc.
    Via Business Wire
    News headline image
    Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
    From Adicet Bio, Inc.
    Via Business Wire
    News headline image
    Adicet Bio Announces FDA Clearance of IND Application for ADI-212
    From Adicet Bio, Inc.
    Via Business Wire
    News headline image
    Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates
    From Adicet Bio, Inc.
    Via Business Wire
    News headline image
    Adicet Bio to Participate in Fireside Chat at Canaccord Genuity 46th Annual Growth Conference
    From Adicet Bio, Inc.
    Via Business Wire
    News headline image
    Adicet Bio to Participate in Fireside Chat at Jefferies Global Healthcare Conference
    From Adicet Bio, Inc.
    Via Business Wire
    News headline image
    Adicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
    From Adicet Bio, Inc.
    Via Business Wire
    News headline image
    Adicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
    From Adicet Bio, Inc.
    Via Business Wire
    News headline image
    Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
    From Adicet Bio, Inc.
    Via Business Wire
    News headline image
    Adicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones
    From Adicet Bio, Inc.
    Via Business Wire
    News headline image
    Adicet Bio Announces Reverse Stock Split
    From Adicet Bio, Inc.
    Via Business Wire
    News headline image
    Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
    From Adicet Bio, Inc.
    Via Business Wire
    News headline image
    Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates
    From Adicet Bio, Inc.
    Via Business Wire
    News headline image
    Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From Adicet Bio, Inc.
    Via Business Wire
    News headline image
    Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference
    From Adicet Bio, Inc.
    Via Business Wire
    News headline image
    Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)
    From Adicet Bio, Inc.
    Via Business Wire
    News headline image
    Adicet Bio, Inc. Announces $80 Million Registered Direct Offering
    From Adicet Bio, Inc.
    Via Business Wire
    News headline image
    Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)
    From Adicet Bio, Inc.
    Via Business Wire
    News headline image
    Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
    From Adicet Bio, Inc.
    Via Business Wire
    News headline image
    Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference
    From Adicet Bio, Inc.
    Via Business Wire
    News headline image
    Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From Adicet Bio, Inc.
    Via Business Wire
    News headline image
    Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates
    From Adicet Bio, Inc.
    Via Business Wire
    News headline image
    Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference
    From Adicet Bio, Inc.
    Via Business Wire
    News headline image
    Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases
    From Adicet Bio, Inc.
    Via Business Wire
    News headline image
    Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference
    From Adicet Bio, Inc.
    Via Business Wire
    News headline image
    Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates
    From Adicet Bio, Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 6 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.